How next-generation sequencing will change clinical practice
Chng Wee Joo
Why novel multiple myeloma drugs are expensive
Trial results and drug combinations for bortezomib in multiple myeloma
Can we cure 50% of all multiple myeloma patients in the next five years?
Transplant vs no transplant: the IFM 2009 clinical trial in multiple myeloma